Advantage

Adverse Event (AD1)

Version: 1.01; 12-10-20

4

- (\$sitecode)

Adverse event onset date (AEDATE):

Sequence number (AESEQNO):

This adverse event has been closed by the Medical Reviewer and may no longer be updated.

For the purpose of this protocol, Adverse Events are captured on the Targeted Safety Events form. Only Serious Adverse Events are reported on this form.

1. Adverse event name:(A1DESCPT)	
2. Date site became aware of the event: (A1AWARDT)	(mm/dd/yyyy)
3. Severity of event: (A1SEVRTY)	
	01-Grade 1 - Mild
	02-Grade 2 - Moderate 03-Grade 3 - Severe
	0-No 1-Yes
a. If "Yes", action taken with study medication:(A1MEDACT)	00-None
	01-Decreased drug
	02-Increased drug
	03-Temporarily stopped drug
	04-Permanently stopped drug 05-Participant terminated from study
5. If not caused by the study medication, alternative etiology:(A1ALTETI)	00-None apparent
	01-Study disease
	02-Concomitant medication
	03-Other pre-existing disease or condition
	04-Accident, trauma, or external factors
	*Additional Options Listed Below
a. If "Other", Specify:(A1ALTSP)	
6. Outcome of event: (A1OUTCM)	
	01-Recovering/resolving
	02-Recovered/resolved 03-Recovered/resolved with sequelae
	04-Not recovered/not resolved
	05-Fatal
	97-Unknown
7. Date of resolution or medically stable:(A1RESDT)	(mm/dd/yyyy)
	se Event (SAE). The Serious Adverse Event Summary (AD2) form should be completed for al
Serious Adverse Events reported. 8. Was this event associated with:	
If more than one option applies, select the most serious.	
	0-No 1-Yes
 b. Did the adverse event result in persistent or significant disability or incapacity? (A1DISABL) 	0-No 1-Yes
c. Did the adverse event result in death?(A1DTH)	0-No 1-Yes
1. If "Yes", date of death:(A1DTHDT)	(mm/dd/yyyy)
 d. Did the adverse event result in initial or prolonged hospitalization for the participant? (A1HOSP) If "Yes". 	0-No 1-Yes
1. Date of hospital admission:(A1HOSPAD)	(mm/dd/yyyy)
2. Date of hospital discharge:(A1HOSPDC)	(mm/dd/yyyy)
e. Is the adverse event life threatening?(A1LIFETH)	0-No 1-Yes
f. Is the adverse event an "other serious" event (Important Medical Event)?(A1OTCRIT)	
Comments:(AD1COMM)	

Additional Selection Options for AD1

Sequence number (AESEQNO) (key field):

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 09-9th Adverse Event of the day

If not caused by the study medication, alternative etiology:

05-Concurrent illness/condition (not pre-existing) 06-Study procedures 07-Naloxone challenge 99-Other

	Advantage Advanta	age eClinical		🗍 - (\$sitecode) 🔒
		Serious Adverse Event Sum	mary (AD2)	
Ad	verse event onset date <i>(AEDATE</i>): Sequence number <i>(AESEQNO</i>):			Version: 3.00; 07-02-21
т	his adverse event has been closed by the Medical	Reviewer and may no longer be updated.		
1. lı	itial narrative description of serious adverse event:(A2	SUMM)		
A	elevant past medical history:(A2SAEMHX) Ilergies, pregnancy, smoking and alcohol use, hyperter \2MEDHX)	00-No 01-Yes	97-Unknown	
	edications at the time of the event:(A2SAEMED) e sure to assess for dosage and date of last dose for t	00-No 01-Yes		
	Medication (Generic Name)	Indication		
			1	

a. (A2_01DNM)	(A2_01DIN)
b. (A2_02DNM)	(A2_02DIN)
c. (A2_03DNM)	(A2_03DIN)
d. (A2_04DNM)	(A2_04DIN)
e. (A2_05DNM)	(A2_05DIN)
f. (A2_06DNM)	(A2_06DIN)
g. (A2_07DNM)	(A2_07DIN)
h. (A2_08DNM)	(A2_08DIN)
i. (A2_09DNM)	(A2_09DIN)
j. (A2_10DNM)	(A2_10DIN)

4.	Treatments for the event:(A2SAETRT)	🔲 00-No 📘 01-Yes	97-Unknown
	Treatment	Indication	Date Treated (mm/dd/yyyy)
	a. (A2_1TNME)	(A2_1TIND)	(A2_1LTDT)
	b. (A2_2TNME)	(A2_2TIND)	(A2_2LTDT)
	c. (A2_3TNME)	(A2_3TIND)	(A2_3LTDT)
	d. (A2_4TNME)	(A2_4TIND)	(A2_4LTDT)
	e. (A2_5TNME)	(A2_5TIND)	(A2_5LTDT)

5. Labs/tests performed in conjunction with this event:(A2SAELAB)

00-No 01-Yes 97-Unknown

Lab/Test	Findings	Date of Test (mm/dd/yyyy)
a. (A2_1LBNM)	(A2_1LBIN)	(A2_1LBDT)
b. (A2_2LBNM)	(A2_2LBIN)	(A2_2LBDT)
c. (A2_3LBNM)	(A2_3LBIN)	(A2_3LBDT)
d. (A2_4LBNM)	(A2_4LBIN)	(A2_4LBDT)
e. (A2_5LBNM)	(A2_5LBIN)	(A2_5LBDT)

6. Follow-up: Include labs/test results as they become available, clinical changes, consultant diagnosis, etc. (A2FOLLUP)

10313,	010.
- F	
P	

7. Additional information requested by the Medical Monitor: (A2ADDINF)

a. Have all Medical Monitor requests been addressed?(A2RQADDR)

01-Yes

Additional Selection Options for AD2

Sequence number (AESEQNO) (key field):

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 08-8th Adverse Event of the day 10-10th Adverse Event of the day

Advantage Advantage eClinical		☐ - (\$sitecode) ▲
Serious Advo	erse Event Medical (AD3)	
Adverse event onset date (AEDATE): Sequence number (AESEQNO):		Version: 1.01; 12-10-20
1. Was this determined to be a serious adverse event?(A3SAE)	0-No 1-Yes	
2. Was this event considered associated with the study medication?(A3RELDRG)	00-No 01-Yes 96-N/A	
3. Was this event expected?(A3EXPECT)	0-No 1-Yes	
4. Is this a standard expedited/reportable event (i.e., is it serious, unexpected and related to therapy)?(A3EXPFDA)	00-No 01-Yes 96-N/A	
a. If "No", is this an expedited/reportable event for other reasons?(A3EXPOTH)	0-No 1-Yes	
5. Does the protocol need to be modified based on this event?(A3MPROT)	0-No 1-Yes	
6. Does the consent form need to be modified based on this event?(A3MCNST)	0-No 1-Yes	
7. Is the review complete?(A3REVDNE)	0-No 1-Yes	
a. If "No", what additional information is required:(A3ADDINF)		
Assessed by:(A3ASRID)	(initials)	
Reviewed by:(A3REVID)	(initials)	
Comments:(A3COMM)		

Additional Selection Options for AD3

Sequence number (AESEQNO) (key field):

01-1st Adverse Event of the day 02-2nd Adverse Event of the day 03-3rd Adverse Event of the day 04-4th Adverse Event of the day 05-5th Adverse Event of the day 06-6th Adverse Event of the day 07-7th Adverse Event of the day 09-9th Adverse Event of the day 10-10th Adverse Event of the day

Advantage Advantage eClinical	🗍 – (\$sitecode) 🔒
Concomitar	t Medications (CMX)
Segment <i>(PROTSEG)</i> : B, E Visit Number <i>(VISNO)</i> :	Version: 1.01; 05-19-21
Date of assessment:(CMXASMDT)	(mm/dd/yyyy)
Please use this form to capture concomitant medications taken in the past week other th Medications 1.(CMMED01)	
2.(CMMED02)	
3.(CMMED03)	
4.(CMMED04)	
5.(CMMED05)	
6.(CMMED06)	
7.(CMMED07)	
8.(CMMED08)	
9.(CMMED09)	
10.(C MMED10)	
Comments:(CMXCOMM)	

Advantage eClinical	Advanta	ge eCli	nical		
			Clinic l	Jrine Toxic	cology (CUT)
egment (<i>PROTSEG</i>): B, C, D, E equence number (<i>SEQNUM2</i>):					
Date of assessment:(CUTASMDT) N as a urine drug screen performed?(UI	DTEST1)			0-No	(<i>mm/dd/yyyy</i>) 1-Yes
a. If "No", reason: <i>(UDNORSN1)</i>				02-Particip 04-Study s 92-COVID-	-19: Illness -19: Public health measures
1. If "Other", specify:(UDNOSP1)					
Date urine specimen collected:(UDCOL	DT)				(mm/dd/yyyy)
Was the urine specimen temperature wi	• •	<i>,</i> ,	EMP1)	00-No	01-Yes 97-Not measured
Was the urine specimen determined to I Urine Drug Screen Result(s):	be adulterated?(U	IDADULT1)		🗌 00-No	01-Yes 97-Not measured
Drug Name (Abbreviation)	00- Negative	01- Positive	02- Invalid	97- Not Measured	
Amphetamine (500 ng) (AMP):	(UDAMP1)				
Barbiturate (300 ng) (BAR):	(UDBAR1)				
Buprenorphine (10 ng) (BUP):	(UDBUP1) 🔲				
Benzodiazepines (300 ng) (BZO):	(UDBZO1)				
Cocaine (150 ng) (COC):					
Ecstasy (500 ng) (MDMA):	(UDMDA1)				
Methamphetamine (500 ng) (MET):	(UDMET1)				
Methadone (300 ng) (MTD):	(UDMTD1)				
Opiates (300 ng) (OPI):	(UDOPI31) 🔲				
Oxycodone (100 ng) (OXY):	(UDOXY1)				

(UDPCP1) 🔲

(UDTHC1) 🔲

(UDFEN1)

Comments:(CUTCOMM)

Phencyclidine (25 ng) (PCP):

Marijuana (50 ng) (THC):

Fentanyl (20 ng) (FEN):

ł	

🔲 - (\$sitecode)

4

Version: 1.01; 02-15-22

Additional Selection Options for CUT

Sequence number (SEQNUM2) (key field):

01-1

02-2

03-3

04-4

05-5

06-6 07-7

08-8

09-9

10-10



DSM-5 Checklist (DSM)

Γ

Version: 1.01; 03-02-21

Segment (PROTSEG): B Visit Number (VISNO):

Date of assessment:(DSMASMDT)


(mm/dd/yyyy)


	Opioids	Alcohol	Amphetamines	Cannabis	Cocaine	Sedatives
1 Have you used [insert substance] in the past 12 months?	No Yes (DSOPI12M)	No Yes (DSALC12M)	No Yes (DSAMP12M)	No Yes (DSTHC12M)	No Yes (DSCOC12M	No Yes (DSSED12M)
2 Suggested prompt: "Have you often found that when you start using [insert substance], you ended up taking more than you intended to? For example, you planned to have a small amount of [insert substance], but you needed up having much more; or you ended up using for a longer period than intended?" The substance is often taken in larger amounts or over a longer period than was intended:	No Yes	No Yes	No Yes	No Yes	No Yes	No Yes
3 Suggested prompt: "Have you wanted to stop or cut down or control your use of [insert substance]?"	No Yes	No Yes	No Yes	No Yes	No Yes	No Yes
There is a persistent desire or unsuccessful efforts to cut down or control substance use:	(DSOPICUT)	(DSALCCUT)	(DSAMPCUT)	(DSTHCCUT)	(DSCOCCUT)	(DSSEDCUT
4 Suggested prompt: "Have you spent a lot of time getting or using [insert substance]? Or has it taken a lot of time for you to get over the effect?"	No Yes	No Yes	No Yes	No Yes	No Yes	No Yes
A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects:	(DSOPITIM)	(DSALCTIM)	(DSAMPTIM)	(DSTHCTIM)	(DSCOCTIM)	(DSSEDTIM)
5 Suggested prompt: "Have you had a strong desire or urge to use [insert substance] in between those times when you were using? Has there been a time when you had such strong cravings or urges to use that you had trouble thinking about anything else?"	No Yes	No Yes	No Yes	No Yes	No Yes	No Yes
Craving or a strong desire or urge to use a specific substance:	(DSOPICRA)	(DSALCCRA)	(DSAMPCRA)	(DSTHCCRA)	(DSCOCCRA)	(DSSEDCRA)

	Opioids	Alcohol	Amphetamines	Cannabis	Cocaine	Sedatives
6 Suggested prompt: "Have you missed work or school or often arrived late because you were intoxicated, high or recovering from the night before? How about not taking care of things at home because of your use?"						
Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (e.g., repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; neglect of children or household):	(DSOPIOBL)	(DSALCOBL)	(DSAMPOBL)	(DSTHCOBL)	(DSCOCOBL)	(DSSEDOBL)
7 Suggested prompt: "Have you continued to use even though you knew that the drug caused you problems like making you depressed, anxious, agitated or irritable? Has your use ever caused physical problems like heart palpitations, trouble breathing or constipation?"				<u> </u>		· · · · ·
The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance:	(DSOPICON)	(DSALCCON)	(DSAMPCON)	(DSTHCCON)	(DSCOCCON)	(DSSEDCON
8 Suggested prompt: "Have you had to give up or spend less time working, enjoying hobbies, or being with others because of your drug use?"						
Important social, occupational, or recreational activities are given up or reduced because of substance use:	(DSOPIACT)	(DSALCACT)	(DSAMPACT)	(DSTHCACT)	(DSCOCACT)	(DSSEDACT)
9 Suggested prompt: "Have you ever gotten high before doing something that requires coordination or concentration like driving, boating, climbing a ladder, or operating heavy machinery?"						
Recurrent substance use in situations in which it is physically hazardous (e.g., driving an automobile or operating a machine when impaired by substance use):	(DSOPIHAZ)	(DSALCHAZ)	(DSAMPHAZ)	(DSTHCHAZ)	(DSCOCHAZ)	(DSSEDHAZ)
10 Suggested prompt: "Has your use of [insert substance] caused problems with other people such as with family members, friends or people at work? Did you get into arguments about your use or fights when you are using? Did you keep using despite these problems?"						
Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (e.g., arguments with spouse about consequences of intoxication, physical fights):	(DSOPISOC)	(DSALCSOC)	(DSAMPSOC)	(DSTHCSOC)	(DSCOCSOC)	(DSSEDSOC)



Opioids	Alcohol	Amphetamines	Cannabis	Cocaine	Sedatives
(DSOPITOL)	(DSALCTOL)	(DSAMPTOL)	(DSTHCTOL)	(DSCOCTOL)	(DSSEDTOL)
(DSOPIWIT)	(DSALCWIT)	(DSAMPWIT)	(DSTHCWIT)	(DSCOCWIT)	(DSSEDWIT)
Opioids	Alcohol	Amphetamines	Cannabis	Cocaine	Sedatives
(DSOPISO)	(DSALCSO)	(DSAMPSO)	(DSTHCSO)	(DSCOCSO)	(DSSEDSO)
	(DSOPIWIT) Opioids	(DSOPITOL) (DSALCTOL) (DSOPIWIT) (DSALCWIT) (DSOPIWIT) (DSALCWIT) (DSALCWIT)		(DSOPITOL) (DSALCTOL) (DSAMPTOL) (DSTHCTOL) (DSOPIWIT) (DSALCWIT) (DSAMPWIT) (DSTHCWIT) (DSOPIWIT) (DSALCWIT) (DSAMPWIT) (DSTHCWIT) (DSOPIWIT) (DSALCMIT) (DSAMPWIT) (DSTHCWIT) (DSOPIWIT) (DSALCWIT) (DSAMPWIT) (DSTHCWIT) (DSOPIWIT) (DSALCWIT) (DSAMPWIT) (DSTHCWIT)	Image: Normal stateImage: Normal stateImage: Normal stateImage: Normal state(DSOPITOL)(DSALCTOL)(DSAMPTOL)(DSTHCTOL)(DSCOCTOL)(DSOPIWIT)(DSALCWIT)(DSAMPWIT)(DSTHCWIT)(DSCOCWIT)(DSOPIWIT)(DSALCWIT)(DSAMPWIT)(DSTHCWIT)(DSCOCWIT)(DSOPIMIT)(DSALCWIT)(DSAMPWIT)(DSTHCWIT)(DSCOCWIT)(DSOPIMIT)(DSALCWIT)(DSAMPWIT)(DSTHCWIT)(DSCOCWIT)(Diright stateAlcoholAmphetaminesCannabisCocaine





Advantage Advantage eClinical		🗐 - (\$sitecode) 🔺
C	Death Form (DTH)	Version: 1.00; 02-10-21
 Date of Death:(<i>DTDTHDT</i>) Date staff notified of death:(<i>DTNTFYDT</i>) Date of last contact with participant:(<i>DTCNTCDT</i>) Was there suspected or confirmed opioid overdose?(<i>DTOPIOD</i>) a. If "Yes", date of suspected or confirmed opioid overdose?(<i>DTOPIDT</i>) 	(mm/dd/yyyy) (mm/dd/yyyy) (mm/dd/yyyy) 00-No 01-Yes 97-Unknown (mm/dd/yyyy)	
 5. Primary and secondary causes of death: This should be a "verbatim" extraction of the text from the source document. a. Primary Cause of Death: (DTPCOD) b. Secondary Cause of Death: (DT2COD) 		
6. Source for cause of death: <i>(DTSOURCE)</i>	01-Medical chart 02-Death certificate 03-Autopsy report 04-Treating physician 05-NDI 99-Other	
a. If "Other", specify:(DTSRCESP)		
 7. Was an autopsy performed?(<i>DTAUTPSY</i>) a. If "Yes", can a copy of the autopsy report be obtained?(<i>DTAUTCPY</i>) 8. Did death occur while the participant was hospitalized?(<i>DTHSPDTH</i>) a. If "No", where did the death occur?(<i>DTDTHLOC</i>) 	00-No 01-Yes 97-Unknown 00-No 01-Yes 97-Unknown 00-No 01-Yes 97-Unknown	
 9. Was drug use a contributing factor in the death?(DTDRUG) a. If "Yes", was the drug an opioid?(DTOPIDRG) 10. Was alcohol a contributing factor in the death?(DTALCOHL) 	00-No 01-Yes 97-Unknown 00-No 01-Yes 97-Unknown 00-No 01-Yes 97-Unknown	
11. Short narrative about the circumstance surrounding the death of the participant: (<i>DTNARRTV</i>) Comments:(<i>DTHCOMM</i>)		

If available, upload the autopsy, death report, discharge note, or any other supporting documentation.



Advantage eClinical

📃 - (\$sitecode) 🔒

0097B (ENR)

Version: 2.01; 08-11-21

1. Date of written informed consent:(STARTDT)

2. Was consent for genetics sample obtained?(S97GCSNT) Comments:(S97COMM)

	(mm/dd/yyyy)
🗌 0-No	1-Yes

Medical Psychiatric History (MHX)

Version: 1.00; 01-19-21

4

Segment (PROTSEG): B Visit Number (VISNO):

Date of assessment:(MHXASMDT)

(mm/dd/yyyy)

Medical and Psychiatric History

Medical Condition	History of the Condition	If "Yes", Specify	Condition Present Currently	Medication Taken Currently
1. Eye disorders:	(MHEYEH) 🗌 0-No 🔲 1-Yes	(MHEYESP)	(MHEYEC) 0-No 1-Yes	(MHEYEM) O-No I1-Yes
2. Ear disorders:	(MHEARH) 0-No 1-Yes	(MHEARSP)	(MHEARC) O-No I-Yes	(MHEARM) 🔲 0-No 🔲 1-Yes
3. Respiratory and throat disorders:	(MHRESPH) 🔲 0-No 🔲 1-Yes	(MHRESPSP)	(MHRESPC) 🗌 0-No 🔲 1-Yes	(MHRESPM) 🗌 0-No 🔲 1-Yes
4. Cardiovascular disorders:	(MHCARDH) 🗌 0-No 🔲 1-Yes	(MHCARDSP)	(MHCARDC) O-No I1-Yes	(MHCARDM) 🗌 0-No 🔲 1-Yes
5. Endocarditis:	(MHENDH) 0-No 1-Yes	(MHENDSP)	(MHENDC) 0-No 1-Yes	(MHENDM) O-No I1-Yes
6. Liver and gallbladder disorders:	(MHLIVRH) 🗌 0-No 🔲 1-Yes	(MHLIVRSP)	(MHLIVRC) 0-No 1-Yes	(MHLIVRM) 🗌 0-No 🔲 1-Yes
7. Other gastrointestinal disorders:	(MHGIH) 0-No 1-Yes	(MHGISP)	(MHGIC) 0-No 1-Yes	(MHGIM) 0-No 1-Yes
8. Skin disorders:	(MHSKINH) 🗌 0-No 🗌 1-Yes	(MHSKINSP)	(MHSKINC) 0-No 1-Yes	(MHSKINM) 🗌 0-No 🔲 1-Yes
9. Cellulitis:	(MHCELH) O-No I-Yes	(MHCELSP)	(MHCELC) 0-No 1-Yes	(MHCELM) O-No I-Yes
10. Musculoskeletal disorders:	(MHMUSCH) 🗌 0-No 🔲 1-Yes	(MHMUSCSP)	(MHMUSCC) 🗌 0-No 🔲 1-Yes	(MHMUSCM) 🗌 0-No 🔲 1-Yes
11. Osteomyelitis:	(MHOSTH) 0-No 1-Yes	(MHOSTSP)	(MHOSTC) 0-No 1-Yes	(MHOSTM) 0-No 1-Yes
12. Metabolic disorders:	(MHMETAH) 🗌 0-No 🔲 1-Yes	(MHMETASP)	(MHMETAC) 0-No 1-Yes	(MHMETAM) 🗌 0-No 🔲 1-Yes
13. Endocrine disorders:	(MHENDOH) 0-No 1-Yes	(MHENDOSP)	(MHENDOC) 0-No 1-Yes	(MHENDOM) 🗌 0-No 📋 1-Yes
14. Renal and urinary tract disorders:	(MHRENLH) 0-No 1-Yes	(MHRENLSP)	(MHRENLC) 0-No 1-Yes	(MHRENLM) O-No I1-Yes
15. Reproductive system and breast disorders:	(MHREPOH) 🗌 0-No 🔲 1-Yes	(MHREPOSP)	(MHREPOC) 0-No 1-Yes	(MHREPOM) 0-No 1-Yes
16. Epilepsy or seizure disorder:	(MHELPYH) 🗌 0-No 🔲 1-Yes	(MHELPYSP)	(MHELPYC) 0-No 1-Yes	(MHELPYM) 🗌 0-No 🔲 1-Yes
17. Clinically significant neurological damage:	(MHNEURH) 🗌 0-No 🗌 1-Yes	(MHNEURSP)	(MHNEURC) 0-No 1-Yes	(MHNEURM) 🗌 0-No 🔲 1-Yes
18. Other nervous system disorders:	(MHNERVH) 0-No 1-Yes	(MHNERVSP)	(MHNERVC) 0-No 1-Yes	(MHNERVM) 🗌 0-No 🔲 1-Yes
19. HIV:	(MHHIVH) 0-No 1-Yes	(MHHIVSP)	(MHHIVC) 0-No 1-Yes	(MHHIVM) O-No I1-Yes
20. Hepatitis C:	(MHHEPCH) 🗌 0-No 🔲 1-Yes	(MHHEPCSP)	(MHHEPCC) 0-No 1-Yes	(MHHEPCM) 🗌 0-No 🔲 1-Yes
Psychiatric Condition	History of the Condition	If "Yes", Specify	Condition Present Currently	Medication Taken Currently
21. Anxiety or panic disorder: (MHANXH) 🗌 0-No 🗌 1-Yes	(MHANXSP)	(MHANXC) 🔲 0-No 🗌 1-Yes	(MHANXM) 🗌 0-No 🗌 1-Yes
22. Attention Deficit Hyperactivity Disorder: (MHADHDH) 🗌 0-No 🔲 1-Yes	(MHADHDSP)	(MHADHDC) 🗌 0-No 🔲 1-Yes	(MHADHDM) 🗌 0-No 🔲 1-Yes
23. Bipolar Disorder: (MHBPLRH) 🗌 0-No 🗌 1-Yes	(MHBPLRSP)	(MHBPLRC) 🗌 0-No 🔲 1-Yes	(MHBPLRM) 🗌 0-No 🔲 1-Yes
24. Eating Disorder: (MHEATH) 🗌 0-No 🗌 1-Yes	(MHEATSP)	(MHEATC) 🔲 0-No 🗌 1-Yes	(MHEATM) 🗌 0-No 🗌 1-Yes
25. Major Depressive Disorder:	MHMDDH) 🗌 0-No 🔲 1-Yes	(MHMDDSP)	(MHMDDC) 🗌 0-No 🗌 1-Yes	(MHMDDM) 🗌 0-No 🗌 1-Yes
26. Schizophrenia:	MHSCHZH) 🗌 0-No 🔲 1-Yes	(MHSCHZSP)	(MHSCHZC) 🗌 0-No 🔲 1-Yes	(MHSCHZM) 🗌 0-No 🔲 1-Yes
27. Suicidal ideation:	MHSIDH) 🗌 0-No 🗌 1-Yes	(MHSIDSP)	(MHSIDC) 🔲 0-No 🗌 1-Yes	(MHSIDM) 🗌 0-No 🗌 1-Yes
28. Suicidal behavior: (MHSBEHH) 🗌 0-No 🔲 1-Yes	(MHSBEHSP)	(MHSBEHC) 🗌 0-No 🔲 1-Yes	(MHSBEHM) 🔲 0-No 🔲 1-Yes
29. Homicidal ideation:	MHHIDH) 🗌 0-No 🗌 1-Yes	(MHHIDSP)	(MHHIDC) 🗌 0-No 🗌 1-Yes	(MHHIDM) 🗌 0-No 🗌 1-Yes
30. Homicidal behavior:	MHHBEHH) 🗌 0-No 🔲 1-Yes	(MHHBEHSP)	(MHHBEHC) 🗌 0-No 🔲 1-Yes	(MHHBEHM) 🔲 0-No 🔲 1-Yes
31. Violent behavior:	MHVBEHH) 🗌 0-No 🔲 1-Yes	(MHVBEHSP)	(MHVBEHC) 🗌 0-No 🔲 1-Yes	(MHVBEHM) 🗌 0-No 🔲 1-Yes
32. Psychotic episodes not specified above:	MHPSYEH) 🗌 0-No 🔲 1-Yes	(MHPSYESP)	(MHPSYEC) 🗌 0-No 🗌 1-Yes	(MHPSYEM) 🗌 0-No 🔲 1-Yes
33. Other psychiatric disorder:	MHPSYOH) 🗌 0-No 🔲 1-Yes	(MHPSYOSP)	(MHPSYOC) 🗌 0-No 🔲 1-Yes	(MHPSYOM) 🗌 0-No 🗌 1-Yes

Other Conditions Not Listed Above	Specific Details	Condition Present Currently	Medication Taken Currently
34. (MHOTHR1)	(MHOTH1SP)	(MHOTHR1C) 0-No 1-Yes	(MHOTHR1M) 🗌 0-No 🔲 1-Yes
35. (MHOTHR2)	(MHOTH2SP)	(MHOTHR2C) 🗌 0-No 🗌 1-Yes	(MHOTHR2M) 🗌 0-No 🔲 1-Yes
36. (MHOTHR3)	(MHOTH3SP)	(MHOTHR3C) 🗌 0-No 🗌 1-Yes	(MHOTHR3M) 🗌 0-No 🔲 1-Yes

Medications 37. Are you currently taking any medications?(MHMEDUSE)

0-No 1-Yes

a. If "Yes", what medications are you taking?(MHMEDSP)

History of Surgical/Medical Procedures and Hospitalizations

38. Does the participant have a history of surgical and/or medical procedures and/or medical hospitalizations? 0-No 1-Yes (MHSUGHOS)

If the participant has had major surgery, provide most important/significant surgical/medical event data below, including date of surgery/event. If the participant remembers only the year, then record "06" for the month and "15" for the day.

	Type of Surgery and/or Medical Procedure and/or Medical Hospitalization	Surgery/Procedure Date	
a.(MHSGH1)		(MHSGH1DT) (mm/dd/yyyy	
b.(MHSGH2)		(MHSGH2DT) (mm/dd/yyyy	
c.(MHSGH3)		(MHSGH3DT) (mm/dd/yyyy	
d.(MHSGH4)		(MHSGH4DT) (mm/dd/yyyy	
e.(MHSHG5)		(MHSGH5DT) (mm/dd/yyyy	

Withdrawal

48. 49. 50.

39. On a scale of 0 to 10, how uncomfortable would the participant describe opioid withdrawal to be, with 0 being none, 1 being little discomfort, 5 being moderate discomfort, and 10 being almost unbearable? (MHUNCOMF) Г

Opioid Treatment History

Has the participant previously engaged in MOUD with: If "Yes" , was the treatment successful?

(xx)

40. Sublingual buprenorphine:	(MHSLBUP) 0-No	0 🗌 1-Yes	1	(MHSLBUPS)	🗌 0-No	1-Yes
41. Injectable buprenorphine:	(MHINJBUP) 🔲 0-No	0 🗌 1-Yes		(MHINBUPS)	🗌 0-No	🗌 1-Yes
42. Implantable buprenorphine:	(MHIMPBUP) 🔲 0-No	0 🗌 1-Yes	i.	(MHIMBUPS)	🗌 0-No	🗌 1-Yes
43. Methadone:	(MHMTD) 🔲 0-No	0 🗌 1-Yes		(MHMTDS)	🗌 0-No	1-Yes
44. Oral naltrexone:	(MHORNAL) 🔲 0-No	0 🗌 1-Yes		(MHORNALS)	🗌 0-No	🗌 1-Yes
45. Implantable naltrexone:	(MHIMPNAL) 🔲 0-No	0 🗌 1-Yes		(MHIPNALS)	🗌 0-No	🗌 1-Yes
46. Injectable naltrexone:	(MHINJNAL) 🔲 0-No	0 🗌 1-Yes	i.	(MHIJNALS)	🗌 0-No	🗌 1-Yes
47. Other, specify:(MHOPTXSP)	(MHOPTXOT) 🔲 0-No	0 🗌 1-Yes		(MHOTOPIS)	🗌 0-No	1-Yes
How many times have you attempted opioid detoxification?(MHOPID	TX)		(xx)			
How many did you complete?(MHCOMPLT)			(xx)			
Have you previously attempted induction onto XR-NTX but were not s	successful?(MHNALNOS)	0-No 1-Y	es		
Comments:(MHXCOMM)						

Advantage eClinical

Advantage eClinical

Pregnancy and Birth Control Assessment (PBC)

Version: 1.00; 01-19-21

4

🔲 - (\$sitecode)

Segment (PROTSEG): B, C, D, E	
Visit Number (VISNO):	

Complete this form only for biologically female participants. Date of assessment:(PBCASMDT)	(mm/dd/yyyy)
1. Is the participant of childbearing potential?(PBCHILD)	0-No 1-Yes
2. Is the participant breastfeeding?(PBBSTFED)	0-No 1-Yes
3. Does the participant agree to use an acceptable method of birth control?(PBUSEBC)	0-No 1-Yes
lf "Yes", select all that apply: a. Oral contraceptives: <i>(PBORALCN)</i>	0-No 1-Yes
b. Contraceptive patch:(PBPATCH)	0-No 1-Yes
c. Barrier (diaphragm or condom):(PBBARRIR)	□ 0-No □ 1-Yes
d. Levonorgestrel implant:(PBLEVIMP)	0-No 1-Yes
e. Medroxyprogesterone acetate injection:(PBMEDINJ)	
f. Complete abstinence from sexual intercourse: (PBABSTIN)	0-No 1-Yes
g. Hormonal vaginal contraceptive ring: (PBRING)	0-No 1-Yes
h. Surgical sterilization:(PBSURGSZ)	0-No 1-Yes
i. Intrauterine contraceptive device (IUD):(PBINTDEV)	0-No 1-Yes
j. Other:(PBBCOTH)	0-No 1-Yes
1.If "Other", specify:(PBBCOSP)	
4. Was a pregnancy test performed?(PBPRGTST)	0-No 1-Yes
a. Date of pregnancy test:(PBPTSTDT)	(mm/dd/yyyy)
b. Result of pregnancy test:(PBRESULT)	00-Negative 01-Positive

Positive results must be reported on the Confirmed Pregnancy and Outcome form.

Comments:(PBCCOMM)

Advantage

Protocol Deviation (PDV)

Version: 2.02; 02-24-22

Date of deviation (PDDATE): Protocol deviation number (PDSEQNO):

Select related participants:

- 1. Is this deviation related to one or more participants?(PDPPTREL)
- a. If "Yes", how many participants?(PDPRELNO)

0-No 1-Yes
01-1
03-3
04-4 05-5
*Additional Options Listed Below

Participant ID 1:(PDPPT01)
Participant ID 2:(PDPPT02)
Participant ID 3:(PDPPT03)
Participant ID 4:(PDPPT04)
Participant ID 5:(PDPPT05)
Participant ID 6:(<i>PDPPT06)</i>
Participant ID 7:(<i>PDPPT07</i>)
Participant ID 8:(<i>PDPPT08)</i>
Participant ID 9:(<i>PDPPT09</i>)
Participant ID 10: <i>(PDPPT10)</i>
Participant ID 11:(<i>PDPPT11)</i>
Participant ID 12:(<i>PDPPT12</i>)
Participant ID 13:(<i>PDPPT13</i>)
Participant ID 14:(<i>PDPPT14)</i>
Participant ID 15:(<i>PDPPT15</i>)
Participant ID 16:(PDPPT16)
Participant ID 17:(PDPPT17)
Participant ID 18:(<i>PDPPT18</i>)

Participant ID 19:(PDPPT19)

9999999999999999-DUMMYPARTICIPANTID
9999999999999999-DUMMYPARTICIPANTID

Participant ID 20:(<i>PDPPT20</i>)	9999999999999-DUMMYPARTICIPANTID
2. Date deviation identified:(PDVDATE)	(mm/dd/yyyy)
3. Deviation type: <i>(PDTYPE)</i>	010-INFORMED CONSENT/ASSENT PROCEDURES 01A No consent/assent obtained 01B Unauthorized assessments and/or procedures conducted prior to obtaining informed consent/assent 01C Non IRB approved/outdated/obsolete informed consent/assent documents used 01Y Other major informed consent/assent procedures issues (specify) *Additional Options Listed Below
a. If "Other", specify: <i>(PDTYPSP)</i>	
4. Reason for Protocol Deviation: (select all that apply) a. Research staff error:(PDRSSTFF)	0-No 1-Yes
b. Hospital error:(PDRSHSP)	0-No 1-Yes
c. Laboratory error: (PDRSLAB)	
d. Pharmacy error:(PDRSPHRM)	0-No 1-Yes
e. Equipment/supply failure:(PDRSEQSP)	
f. Issue with Advantage eClinical (e.g., system down, system glitch):(PDRSEDC)	
g. Participant unable to comply: (PDRSPTNC)	
h. Participant refusal: (PDRSPTRF)	
i. Investigator/study decision: (PDRSINDC)	0-No 1-Yes
j. Other:(PDRSOTHR)	0-No 1-Yes
1. If "Other", specify:(PDRSOTSP)	0-No 1-Yes
5. Is this deviation related to COVID-19?(PDCVD19)	
6. Brief description of what occurred: (PDDESCPT)	0-No 1-Yes
U. Dher description of what occurred. (<i>i DDL301 1)</i>	
7. Was/will there be corrective action for this event?(PDCORRNY)	
a. If "No", describe why corrective action was not or will not be taken:(PDNOCRSP)	0-No 1-Yes
b. If "Yes", which of the following corrective actions were/will be taken: (select all that	apply)
1. Participant consent/reconsent was/will be obtained: (PDCACNST)	0-No 1-Yes
 Research staff corrected/will correct error(s) and/or completed/will complete document(s):(PDCASTCR) 	0-No 1-Yes
 Participant corrected/will correct error(s) and/or completed/will complete document(s):(PDCAPTCR) 	0-No 1-Yes
4. Document(s) was/will be moved to correct file location(s):(PDCADCMV)	0-No 1-Yes
5. Participant was/will be withdrawn from study:(PDCAPTWD)	0-No 1-Yes
6. Study drug administration was/will be halted:(PDCADGSP)	0-No 1-Yes
Study assessment was/will be performed or repeated: (PDCAASAD)	0-No 1-Yes
8. Other:(PDCAOTHR)	0-No 1-Yes
1. If "Other", specify:(PDCAOTSP)	
c. As needed or requested, provide additional details about the corrective action plan:(PDCAPSP)	
8. Brief description of the plan to prevent recurrence: (select all that apply) a. Complete local retraining:(PDPLPTRN)	0-No 1-Yes
1. If "Complete local retraining", specify:(PDPLPSP)	
b. Revise local SOP(s):(PDPLPRV)	0-No 1-Yes
c. Recalibrate/fix or replace faulty equipment/supplies:(PDPLPEQ)	0-No 1-Yes
d. Remove and/or replace incorrect/outdated document(s) from file(s)(PDPLPDOC)	0-No 1-Yes
e. No site action needed: (PDPLPNAN)	
f. Other: (PDPLPOTH)	0-No 1-Yes 0-No 1-Yes
1. If "Other", specify:(PDPLPOSP)	
	,
9. Is this deviation reportable to your IRB?(<i>PDIRBREP</i>) a. If "Yes", will the IRB be notified at the time of continuing review?(<i>PDIRBCON</i>)	0-No 1-Yes 0-No 1-Yes

b. If "Yes", date of planned submission:(PDIRBPDT)

c. If "No", date of actual submission:(PDIRBADT)

Comments:(PDVCOMM)

(mm/dd/yyyy)
(mm/dd/yyyy)

Additional Selection Options for PDV

Protocol deviation number (PDSEQNO) (key field):

Protocol deviation number (PDSEQNO) (key field):
01-1st Protocol Deviation of the day
02-2nd Protocol Deviation of the day
03-3rd Protocol Deviation of the day
04-4th Protocol Deviation of the day
05-5th Protocol Deviation of the day
06-6th Protocol Deviation of the day
07-7th Protocol Deviation of the day
08-8th Protocol Deviation of the day
09-9th Protocol Deviation of the day
10-10th Protocol Deviation of the day
If "Yes", how many participants?
06-6
07-7
08-8
09-9
10-10
11-11
12-12
13-13
14-14
15-15
16-16
17-17
18-18
19-19
20-20
Deviation type:
010 INFORMED CONSENT/ASSENT PROCEDURES
01A No consent/assent obtained
01B Unauthorized assessments and/or procedures conducted prior to obtaining informed consent/assent
01C Non IRB approved/outdated/obsolete informed consent/assent documents used
01Y Other major informed consent/assent procedures issues (specify) 020-INCLUSION/EXCLUSIONCRITERIA
02A Ineligible participant enrolled/inclusion/exclusion criteria not met or eligibility not fully assessed prior to enrollment
02Z Other inclusion/exclusion criteria issues (specify)
040-LABORATORY ASSESSMENTS
04Y Other laboratory assessment issues - Minor (specify)
04Z Other laboratory assessments issues - Major (specify)
050-STUDY PROCEDURES/ASSESSMENTS
05A Study assessment/procedures not followed in accordance with study protocol
05Z Other study procedures/assessments issues (specify)
060-ADVERSE EVENT
06A AE not reported
06B SAE not reported
06C AE/SAE reported out of protocol specified reporting timeframe
06D AE/SAE not elicited, observed and/or documented as per protocol
06E Safety assessment (e.g., labs, ECG, clinical referral to care) not conducted per protocol
06Z Other adverse events issues (specify)
070-RANDOMIZATION PROCEDURES
07A Stratification error
07Z Other randomization procedures issues (specify)
080-STUDY MEDICATION MANAGEMENT
08A Medication not dispensed/administered in accordance with the study protocol
08B Participant use of protocol prohibited medication
08Z Other study medication management issues (specify)
990-OTHER SIGNIFICANT DEVIATIONS
99A Destruction of study materials without prior authorization from sponsor
99B Breach of Confidentiality
99Y Other significant deviations issues - Minor (specify)
99Z Other significant deviations issues - Major (specify)

>	Advantage

Advantage eClinical

Pregnancy Outcome 1 (PO1)

Pregnancy number (PGSEQNUM):

Version: 1.00; 01-19-21

Newborn Information

1. Gender: (PO1GENDR)

2. Gestational age at delivery:(PO1GESWK)

3. Weight at delivery: (PO1WTLBS)

4. Apgar score at 1 minute: (PO1APG1M)

5. Apgar score at 5 minutes:(PO1APG5M)

6. Normal infant?(PO1NORML)

- a. If "No", is there a congenital anomaly?(PO1CONAN)
 - 1. If "Yes", specify abnormality and contributing factors:(PO1ABNSP)

Comments:(PO1COMM)

01-Male 02-Female 97-Unknown
(xx) weeks (PO1GESDY) (x) days (PO1GESUN) OR 97-Unknown
(xx) lbs (PO1WTOZ) (xx) oz (PO1WTUNK) OR 97-Unknown
(xx) (PO11APUK) OR 97-Unknown
(xx) (PO15APUK) OR 97-Unknown
0-No 1-Yes
00-No 01-Yes 97-Unknown
P

Additional Selection Options for PO1

Pregnancy number (PGSEQNUM) (key field):

01-1

02-2 03-3

03-0

04-4

>	Advantage

Advantage eClinical

Pregnancy Outcome 2 (PO2)

Pregnancy number (PGSEQNUM):

Version: 1.00; 01-29-21

Newborn Information

- 1. Gender: (PO2GENDR)
- 2. Gestational age at delivery:(PO2GESWK)
- 3. Weight at delivery: (PO2WTLBS)
- 4. Apgar score at 1 minute: (PO2APG1M)
- 5. Apgar score at 5 minutes:(PO2APG5M)
- 6. Normal infant?(PO2NORML)
- a. If "No", is there a congenital anomaly?(PO2CONAN)
 - 1. If "Yes", specify abnormality and contributing factors: (PO2ABNSP)

Comments:(PO2COMM)

01-Male 02-Female 97-Unknown
(xx) weeks (PO2GESDY) (x) days (PO2GESUN) OR 97-Unkno
(xx) lbs (PO2WTOZ) (xx) oz (PO2WTUNK) OR 97-Unknown
(xx) (PO21APUK) OR 97-Unknown
(xx) (PO25APUK) OR 97-Unknown
0-No 1-Yes
00-No 01-Yes 97-Unknown

Additional Selection Options for PO2

Pregnancy number (PGSEQNUM) (key field):

01-1

02-2

03-3

04-4

>	Advantage

Advantage eClinical

Pregnancy Outcome 3 (PO3)

Pregnancy number (PGSEQNUM):

Version: 1.00; 01-19-21

Newborn Information

1. Gender: (PO3GENDR)

2. Gestational age at delivery:(PO3GESWK)

3. Weight at delivery:(PO3WTLBS)

4. Apgar score at 1 minute:(PO3APG1M)

5. Apgar score at 5 minutes:(PO3APG5M)

6. Normal infant?(PO3NORML)

a. If "No", is there a congenital anomaly?(PO3CONAN)

1. If "Yes", specify abnormality and contributing factors:(PO3ABNSP)

Comments:(PO3COMM)

01-Male 02-Female 97-Unknown
(xx) weeks (PO3GESDY) (x) days (PO3GESUN) OR 97-Unknown
(xx) lbs (PO3WTOZ) (xx) oz (PO3WTUNK) OR 97-Unknown
(xx) (PO31APUK) OR 97-Unknown
(xx) (PO35APUK) OR 97-Unknown
0-No 1-Yes
00-No 01-Yes 97-Unknown
0-No 1-Yes

🔲 - (\$sitecode) 🔒

Additional Selection Options for PO3

Pregnancy number (PGSEQNUM) (key field):

01-1

02-2

03-3

04-4

>	Advantage

Advantage eClinical

Pregnancy Outcome 4 (PO4)

Pregnancy number (PGSEQNUM):

Version: 1.00; 01-19-21

Newborn Information

1. Gender: (PO4GENDR)

2. Gestational age at delivery:(PO4GESWK)

3. Weight at delivery: (PO4WTLBS)

4. Apgar score at 1 minute: (PO4APG1M)

5. Apgar score at 5 minutes:(PO4APG5M)

6. Normal infant?(PO4NORML)

a. If "No", is there a congenital anomaly?(PO4CONAN)

1. If "Yes", specify abnormality and contributing factors:(PO4ABNSP)

Comments:(PO4COMM)

01-Male 02-Female 97-Unknown
(xx) weeks (PO4GESDY) (x) days (PO4GESUN) OR 97-Unknown
(xx) lbs (PO4WTOZ) (xx) oz (PO4WTUNK) OR 97-Unknown
(xx) (PO41APUK) OR 97-Unknown
(xx) (PO45APUK) OR 97-Unknown
0-No 1-Yes
00-No 01-Yes 97-Unknown

🔲 - (\$sitecode) 🔒

Additional Selection Options for PO4

Pregnancy number (PGSEQNUM) (key field):

01-1

02-2

03-3

04-4

Advantage Advantage eClinical		🗐 - (\$sitecode) 🛛 🛔
Confirmed	Pregnancy and Outcome (PRG)	
Pregnancy number (PGSEQNUM) (keyfield): 01-1 02-2 03-3 04-4		Version: 1.00; 12-07-20
Information About Pregnancy		
1. Date on which study staff became aware of pregnancy:(PRGAWRDT)	(mm/dd/yyyy)	
 2. How was the pregnancy confirmed? (select all that apply) a. Urine pregnancy test result: (PRURICNF) b. Serum pregnancy test result: (PRSERCNF) c. Ultrasound result: (PRULTCNF) d. Other: (PROTHCNF) 1. If "Other", specify: (PROTCNSP) 3. Date on which the pregnancy was confirmed: (PRCNFMDT) 4. Action taken with study medication: (PRACTIND) 5. Approximate due date: (PRAPXDDT) 6. Outcome of pregnancy: (PROUTCME) 	<pre>(mm/dd/yyyy) 0-No 1-Yes 0-None 01-Dose reduced 02-Temporarily stopped medication 03-Permanently stopped medication 03-Permanently stopped medication 04-Termination 99-Other 97-Unknown</pre>	
a. If "Other", specify:(<i>PROTCMSP</i>)7. Date of pregnancy outcome:(<i>PROTCMDT</i>)8. Number of live births:(<i>PRNMLIVB</i>)	(<i>mm/dd/yyyyy</i>)	
a. If "0" live births, indicate reason: <i>(PRRSOBSP)</i>	01-1 02-2 03-3 04-4 99-Other 97-Unknown	
Comments:(<i>PRGCOMM</i>)		

	Advantage eClinical	Advantage eClinical
--	------------------------	---------------------

Segment (PROTSEG): B, E Visit Number (VISNO):

Prisoner Status Assessment (PSA)

Version: 2.01; 09-20-21

4

Date of assessment(PSAASMDT)	(mm/dd/yyyy)
A response of "Yes" to any question indicates that the participant meets the OHR	P definition of prisoner; do not enroll participant into study
 Are you currently being made to stay in an institution (such as a substance use treatment program), by sentence of a court, due to a criminal or civil proceeding? (PSINST) 	0-No 1-Yes
a. If "Yes", please describe the situation:(PSINSTSP)	
 Are you currently being detained while awaiting trial, arraignment, or sentencing? (PSTRIAL) 	0-No 1-Yes
 Are you currently being detained as an alternative to criminal prosecution or incarceration in a jail or prison?(PSALTPRS) 	0-No 1-Yes
4. Are you currently under house arrest, such that you are escorted to treatment or, upon discharge from treatment, you will be escorted to jail, prison, or any inpatient overnight facility as required by law?(PSPROBHA)	0-No 1-Yes
5. Does the participant meet the definition of "prisoner" by any local or state regulations? (PSPRISON)	0-No 1-Yes
Comments:(PSACOMM)	

🔲 - (\$sitecode)

Advantage eClinical	Advantage eClinical	🗐 - (\$sitecode) 🔒
	Target	ed Safety Event (TSE)
Segment (<i>PROTSEG</i>): B, C, D, E TSE date (<i>TSDATE</i>): TSE sequence number (<i>TSSEQNO</i>):		Version: 1.00; 01-19-
1. Event type:(<i>TSEVNTYP</i>)		01-Fall event (likely related to medical/psychiatric condition such as dizziness, confusion with head 02-Acute change in mental status (i.e., disorientation, amnesia, cerebrovascular accident, coma) 03-Acute medical complication likely exacerbated by the stress of withdrawal (i.e., hypertensive crisis 04-Acute psychiatric symptoms (i.e., psychosis, hypomania, severe agitation, violence)
2. Specify details of event:(<i>TSDETLSP</i>) 3. Is this event related to study regimen (i 4. Date site became aware of event:(<i>TSA</i>) 5. Severity:(<i>TSSEVERE</i>)	• <i>/ / /</i>	0-No 1-Yes (mm/dd/yyyy) 01-Mild 02-Moderate 03-Severe
6. Is this event a serious adverse event as If "Yes", SAE onset date:(TSSAEDT) If "Yes", please also compete an SAE for the series of the s		0-No 1-Yes (mm/dd/yyyy)
Comments:(<i>TSECOMM</i>)		

Additional Selection Options for TSE

TSE sequence number (TSSEQNO) (key field):

01-1st Targeted Safety Event of the day 02-2nd Targeted Safety Event of the day 03-3rd Targeted Safety Event of the day 04-4th Targeted Safety Event of the day 05-5th Targeted Safety Event of the day 06-6th Targeted Safety Event of the day 07-7th Targeted Safety Event of the day 08-8th Targeted Safety Event of the day 09-9th Targeted Safety Event of the day 10-10th Targeted Safety Event of the day

Advantage eClinical	Advantage eClinical		🗐 - (\$sitecode) 🔺
	Urine	Drug Screen (UDS)	Version: 2.04, 07, 20, 24
Segment (<i>PROTSEG</i>): B, C, D, E Visit Number (<i>VISNO</i>):			Version: 3.01; 07-30-21
Date of assessment:(UDSASMDT)		(mm/dd/yyyy)	
1. Was a urine drug screen performed?(UDTEST1)	0-No 1-Yes	
a. If "No", reason:(UDNORSN1)		01-Participant reported being unable to provide sample	
		02-Participant refused to provide sample	
		04-Study staff error	
		92-COVID-19: Illness	
		93-COVID-19: Public health measures 94-COVID-19: Other	
		99-Other	
1. If "Other", specify:(UDNOSP1)			
First Urine Drug Screen			
2. Date 1 st urine specimen collected:(UD		(mm/dd/yyyy)	

(hh:mm)

0-No 1-Yes

0-No 1-Yes

- 3. Time 1st urine specimen collected:(*UDCOLTM1*)
- 3. Time 1⁻¹ unne specimen collected:(*UDCOLTMT*)
- 4. Was the 1^{st} urine specimen temperature within the range? (90-100 $^\circ \! \mathrm{F})(UDTEMP1)$
- 5. Was the 1st urine specimen determined to be adulterated?(UDADULT1)
- 6. 1st Urine Drug Screen Results:

Drug Name (Abbreviation)	00-Negative	01-Positive	02-Invalid
Amphetamine (500 ng) (AMP):	(UDAMP1)		
Barbiturate (300 ng) (BAR):	(UDBAR1) 🔲		
Buprenorphine (10 ng) (BUP):	(UDBUP1) 🔲		
Benzodiazepines (300 ng) (BZO):	(UDBZO1) 🔲		
Cocaine (150 ng) (COC):	(UDCOC1)		
Ecstasy (500 ng) (MDMA):	(UDMDA1)		
Methamphetamine (500 ng) (MET):	(UDMET1)		
Methadone (300 ng) (MTD):	(UDMTD1)		
Turn urine dip card over			
Opiates (300 ng) (OPI):	(UDOPI31) 🗌		
Oxycodone (100 ng) (OXY):	(UDOXY1)		
Phencyclidine (25 ng) (PCP):	(UDPCP1)		
Marijuana (50 ng) (THC):	(UDTHC1) 🔲		
Single Dipstick			
Fentanyl (20 ng) (FEN):	(UDFEN1) 🔲		

Second Urine Drug Screen

7. If the 1st urine specimen was determined to be adulterated, was a second specimen collected?(*UDTEST2*)
 a. If "No", reason:(*UDNORSN2*)

0-No 1-Yes

01-Participant reported being unable to provide sample 02-Participant refused to provide sample 04-Study staff error 92-COVID-19: Illness 93-COVID-19: Public health measures 94-COVID-19: Other 99-Other

1. If "Other", specify:(UDNOSP2)

8. Time 2nd urine specimen collected:(UDCOLTM2)

9. Was the 2nd urine specimen temperature within the range? (90-100 $^\circ F)(\textit{UDTEMP2})$.

10. Was the 2nd urine specimen determined to be adulterated?(UDADULT2)

Second Urine Drug Screen Results:

Drug Name (Abbreviation)	00-Negative	01-Positive	02-Invalid
Amphetamine (500 ng) (AMP):	(UDAMP2)		
Barbiturate (300 ng) (BAR):	(UDBAR2)		
Buprenorphine (10 ng) (BUP):	(UDBUP2)		
Benzodiazepines (300 ng) (BZO):	(UDBZO2)		
Cocaine (150 ng) (COC):	(UDCOC2)		
Ecstasy (500 ng) (MDMA):	(UDMDA2)		
Methamphetamine (500 ng) (MET):	(UDMET2)		
Methadone (300 ng) (MTD):	(UDMTD2)		
Turn urine dip card over			
Opiates (300 ng) (OPI):	(UDOPI32)		
Oxycodone (100 ng) (OXY):	(UDOXY2)		
Phencyclidine (25 ng) (PCP):	(UDPCP2)		
Marijuana (50 ng) (THC):	(UDTHC2) 🔲		
Single Dipstick			
Fentanyl (20 ng) (FEN):	(UDFEN2)		

Comments:(UDSCOMM)



🗌 0-No 🔲 1-Yes